Contract research organization QPC acquired a majority interest in JSW Life Sciences, an Austrian CRO offering preclinical and clinical Phase II-IV drug development services. The combined entity will be known as QPS JSW.
With central and eastern European operations providing access to large patient populations for trials in a range of diseases, JSW’s clinical operations span complete clinical development from Phase II-IV studies, including project planning, management, trial monitoring, database management, data analysis, and regulatory affairs. The firm has specialist expertise in CNS diseases, combined with additional capabilities in preclinical efficacy studies including in vitro molecular and cellular analyses. JSW in addition offers model organisms for CNS diseases through its transgenic models business, and claims to be the only firm that can combine behavioral analyses with brain neurochemistry, biochemistry, and quantitative histology and histopathology into preclinical research.
Headquartered in Newark (DE), QPS has regional laboratories and testing facilities in Springfield (MO), Groningen (the Netherlands), Hyderabad (India), and Taipei (Taiwan). The firm says acquisition of JSW will enhance its CNS capabilities, enable it to provide clients with new preclinical areas of research, and improve its ability to offer full-service IND-enabling studies. “This strategic expansion in our preclinical service offerings and Phase II-IV clinical capability represents our fifth cross-border acquisition,” comments Ben Chien, QPS CEO. “Clients all over the world will now have access to an even wider range of the exceptional services they have come to expect from QPS, along with an expanding global footprint.”